IC5 Management of GI Flashcards
(80 cards)
what are the emesis pathways in CINV
peripheral pathway
- chemotherapy induces enterochromaffin cells in the GI to release serotonin –> bind to 5HT3 receptors of the vagal afferent triggering ACUTE CINV
central pathway
- chemotherapy induces chemoreceptor trigger zone (CTZ) in the CNS –> substance P release –> activate NK1 receptor –> trigger DELAYED CINV.
what are the different types of CINV?
acute
delayed
breakthrough
anticipatory
refractory
describe acute CINV
onset 1-2 hours after chemotherapy
peak 5-6 hours
resolution 24hours
describe delayed CINV
onset 48-72 hours
diminish after 1-3 days.
describe anticipatory CINV
uncontrolled emesis prior to chemotherapy, associated with environmental cues eg smell of chemotherapy room
describe breakthrough CINV vs refractory CINV
breakthrough = N/V despite preventive therapy
refractory = N/V in subsequent cycles when antiemetic prophylaxis or rescue therapy has failed in previous cycles
what are the patient risk factors for CINV?
1) young age <50
2) female gender
3) hx of chemo related emesis
4) hx of motion sickness
5) hx of emesis in past pregnancy
6) anxiety
7) low prior alcohol intake <1 glass per day
(1 and 2 impt, commonly missed out)
what is the low risk antiemetic regimen
5HT3
or
DEXA
or DOPA
(no need for delayed treatment)
what is the high risk antiemetic regiment
d1 (acute) GIVEN BEFORE CHEMOTHERAPY
NK1 + 5HT3 + DEXA
+/- olanzapine
(delayed)
DEXA (d2-4)
+/- olanzapine (d2-4 if added previously)
what is the minimal risk antiemetic regimen
should not be offered routine prophylaxis
what is the moderate risk antiemetic regiment
d1 (acute)
5HT3 + DEXA
(delayed)
DEXA (d2-3)
what is the dose of nk1 antagonist
aprepitant (emend)
PO 125mg day1
80mg d2,3
what is the dose of 5HT3 antagonist
IV/PO ondansetron 8-16mg OD d1
IV/PO granisetron 1mg OD d1
what is the dexamethasone dose
IV/PO 12mg OD day 1
IV/PO 8mg OD day 2 onwards
what is the combination 5HT3 + NK1 antagonist dose?
akynzeo = netupitant 300mg + palonosetron 0.5mg
PO 1 cap OD day 1
what is the dopamine antagonist dose
metoclopramide IV/PO 10mg OD-TDS
side effects of nk1 receptors antagonist (common)
fatigue
weakness
hiccups
nausea
what is the moa of nk1 receptor antagonist
prevents substance p from binding to the receptor thus reducing vagal afferent signals to exert antiemetic effect
side effects of akynzeo
headache
constipation
mild fatigue
drug interactions of nk1 receptors antagonist
warfarin (2c9 induction)
steroids (3a4 inhibition) eg budesonide
benzodiazepines (increased BZP conc due to reduced metabolism; 3a4 inhibition) eg diazepam
some chemotherapy agents like ifosfamide (decrease ifosfamide metabolism)
due to inhibition of CYP3A4 and induction of 2C9
moa of 5ht3 receptor antagonists?
blocks 5ht3 receptors peripherally in the gi tract
and
centrally in the medulla
what are the comparisons between the diff 5ht3RA available?
ondansetron = shortest acting
granisetron = intermediate acting (expensive)
palanosetron = longest acting
SE of 5HT3 RA
headache and consitpaiton
rare: QTC prolongation
(caution in patients with underlying cardiac disease eg bradycardia, CHF, electrolyte abnormalities.
ADR of dexa
common: transient increase in glucose, insomnia (dont take late at night),
anxiety,
gastric upset (take with food)
less common: psychosis,
reactivation of ulcers